menu
    • menu
    [{"orgOrder":0,"company":"The Texas A&M University System","sponsor":"Engrail Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Elesclomol","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"The Texas A&M University System","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"The Texas A&M University System \/ Engrail Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"The Texas A&M University System \/ Engrail Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals for Elesclomol

    Menu

    Elesclomol

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            The Texas A&M University System

                            Country arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            The Texas A&M University System

                            Country arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Elesclomol

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Sponsor : Engrail Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Engrail Therapeutics and The Texas A&M University System Enter Licensing Agreement for Elesclomol in Disorders

                            Details : The deal grants Engrail rights to intellectual property for the use of elesclomol. Engrail explore the potential of elesclomol-copper to significantly alter the course of mortality and morbidity for Mitochondrial copper metabolism disorders.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 08, 2021

                            Lead Product(s) : Elesclomol

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Sponsor : Engrail Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth